Retatrutide is an advanced triple hormone receptor agonist that simultaneously stimulates GLP-1, GIP, and glucagon receptors. In cutting-edge metabolic research, this peptide has demonstrated significant reductions in body weight and improvements in glycemic control.
Research focuses include:
-
Triple hormone pathway modulation for enhanced energy expenditure and reduced appetite.
-
Advanced obesity research, showing greater efficacy than dual-agonist treatments like Tirzepatide.
-
Improvements in insulin action, lipid profile, and fatty liver models.
-
Increased thermogenesis and metabolic rate, driven by glucagon receptor activity.
Retatrutide represents the next evolution in incretin-based research for weight loss and metabolic disease management.
Reconstitution Instructions:
Reconstitute with BAC water. Refrigerate after reconstitution and use under sterile research conditions. Use our Peptide Calculator
For research purposes only. Not for human consumption.


Reviews
There are no reviews yet.